Business Context and Reporting Period
This Form 8-K filing by Spherix Incorporated (SPEX) reports on a special meeting of stockholders held on September 5, 2019. The filing details the results of two proposals submitted to security holders regarding capital structure adjustments and compliance with Nasdaq listing rules.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders approved two significant proposals at the meeting, where approximately 67.8% of the total outstanding voting power was represented:
- Proposal 1 (Issuance Approval): Approved the issuance of Common Stock and shares underlying Series L Convertible Preferred Stock in an amount equal to or exceeding 20% of outstanding common stock. This issuance is tied to an Asset Purchase Agreement with CBM BioPharma, Inc.
- Votes For: 510,731
- Votes Against: 276,589
- Abstentions: 38,397
- Broker Non-Votes: 771,272
- Proposal 2 (Charter Amendment): Approved an amendment to the Amended and Restated Certificate of Incorporation to decrease the number of authorized Common Stock shares from 100,000,000 to 99,000,000.
- Votes For: 1,525,605
- Votes Against: 25,116
- Abstentions: 46,268
- Broker Non-Votes: 0
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the asset purchase. The primary purpose of the filing is to disclose the successful completion of the shareholder vote required to proceed with the CBM BioPharma transaction and the reduction of authorized shares.
Key Facts for Investor Verification
- Verify the terms of the Asset Purchase Agreement with CBM BioPharma, Inc. dated May 15, 2019, and its amendment dated May 30, 2019, to understand the dilution impact of the Series L Preferred Stock.
- Confirm the final number of shares issued post-transaction to ensure compliance with the 20% threshold approved by shareholders.
- Review the updated capitalization table to reflect the reduction of authorized shares to 99,000,000.
- Note the significant number of broker non-votes (771,272) on Proposal 1, indicating a large portion of shares held in street name did not receive voting instructions.